By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biopure Corporation 

11 Hurley Street

Cambridge  Massachusetts  02141  U.S.A.
Phone: 617-234-6500 Fax: 617-234-6505

Biopure gives new meaning to blood work. The company makes an artificial blood product based on bovine red blood cells to deliver oxygen to patients with acute blood loss, anemia, or who have had a stroke or a heart attack. Its Hemopure, for humans, and Oxyglobin, for dogs (already approved for veterinary use), are made of purified and processed cow blood, have a two-year shelf life, do not require blood typing, and release more oxygen than a blood transfusion. The blood products also are less viscous than red blood cells, allowing them to flow more easily through partially blocked or constricted blood vessels. Chairman and CEO Carl Rausch owns about 44% of the company.

Last updated: 8-28-01

Key Statistics

Ownership: Public

Web Site: Biopure Corporation
Employees: 177
Symbol: BPUR


Company News
Biopure Corporation (BPUR) Auctions Assets to OPK Biotech for $4 Million 8/28/2009 7:00:29 AM
Biopure Corporation (BPUR) Receives Notice of Delisting from Nasdaq 7/19/2009 10:51:08 PM
Biopure Corporation (BPUR) Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code 7/17/2009 6:52:21 AM
Biopure Corporation (BPUR) Receives Notice of Nasdaq Delisting 6/30/2009 8:47:59 AM
Biopure Corporation (BPUR) Release: U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold 5/18/2009 8:22:34 AM
Biopure Corporation (BPUR) Receives Notices About Nasdaq Listing Compliance 3/31/2009 11:32:24 PM
Biopure Corporation (BPUR) Exploring Strategic Options 2/18/2009 7:54:04 AM
Biopure Corporation (BPUR) Release: U.S. Navy Requested Operations Trial on FDA Hold 1/2/2009 11:03:28 AM
Biopure Corporation (BPUR) Receives Extension of Time to Regain NASDAQ Listing Compliance 1/2/2009 10:55:28 AM
Biopure Corporation (BPUR) Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 12/17/2008 8:19:30 AM